Angiotensin converting enzyme inhibitors (ACE inhibitors) are medications that slow (inhibit) the activity of the enzyme ACE, which decreases the production of angiotensin II.
The global Angiotensin Converting Enzyme Inhibitors market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Angiotensin Converting Enzyme Inhibitors 91制片厂.
According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Angiotensin Converting Enzyme Inhibitors market with multiple angles, which provides sufficient supports to readers鈥� strategy and decision making.
By Company
Pfizer
AstraZeneca
Novartis AG
Daiichi Sankyo, Inc
Sanofi
Merck
Abbott
Segment by Type
Benazepril (Lotensin)
Captopril
Enalapril (Vasotec)
Fosinopril
Lisinopril (Prinivil, Zestril)
Moexipril
Perindopril
Quinapril (Accupril)
Ramipril (Altace)
Trandolapril
Segment by Application
Coronary Artery Disease
Heart Failure
Diabetes
Chronic Kidney Diseases
Heart Attacks
Scleroderma
Migraines
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Angiotensin Converting Enzyme Inhibitors report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies鈥� Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies鈥� Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Angiotensin Converting Enzyme Inhibitors Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Benazepril (Lotensin)
1.2.3 Captopril
1.2.4 Enalapril (Vasotec)
1.2.5 Fosinopril
1.2.6 Lisinopril (Prinivil, Zestril)
1.2.7 Moexipril
1.2.8 Perindopril
1.2.9 Quinapril (Accupril)
1.2.10 Ramipril (Altace)
1.2.11 Trandolapril
1.3 Market by Application
1.3.1 Global Angiotensin Converting Enzyme Inhibitors Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Coronary Artery Disease
1.3.3 Heart Failure
1.3.4 Diabetes
1.3.5 Chronic Kidney Diseases
1.3.6 Heart Attacks
1.3.7 Scleroderma
1.3.8 Migraines
1.3.9 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Angiotensin Converting Enzyme Inhibitors Market Perspective (2018-2029)
2.2 Angiotensin Converting Enzyme Inhibitors Growth Trends by Region
2.2.1 Global Angiotensin Converting Enzyme Inhibitors Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Angiotensin Converting Enzyme Inhibitors Historic Market Size by Region (2018-2023)
2.2.3 Angiotensin Converting Enzyme Inhibitors Forecasted Market Size by Region (2024-2029)
2.3 Angiotensin Converting Enzyme Inhibitors Market Dynamics
2.3.1 Angiotensin Converting Enzyme Inhibitors Industry Trends
2.3.2 Angiotensin Converting Enzyme Inhibitors Market Drivers
2.3.3 Angiotensin Converting Enzyme Inhibitors Market Challenges
2.3.4 Angiotensin Converting Enzyme Inhibitors Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Angiotensin Converting Enzyme Inhibitors Players by Revenue
3.1.1 Global Top Angiotensin Converting Enzyme Inhibitors Players by Revenue (2018-2023)
3.1.2 Global Angiotensin Converting Enzyme Inhibitors Revenue Market Share by Players (2018-2023)
3.2 Global Angiotensin Converting Enzyme Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Angiotensin Converting Enzyme Inhibitors Revenue
3.4 Global Angiotensin Converting Enzyme Inhibitors Market Concentration Ratio
3.4.1 Global Angiotensin Converting Enzyme Inhibitors Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Angiotensin Converting Enzyme Inhibitors Revenue in 2022
3.5 Angiotensin Converting Enzyme Inhibitors Key Players Head office and Area Served
3.6 Key Players Angiotensin Converting Enzyme Inhibitors Product Solution and Service
3.7 Date of Enter into Angiotensin Converting Enzyme Inhibitors Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Angiotensin Converting Enzyme Inhibitors Breakdown Data by Type
4.1 Global Angiotensin Converting Enzyme Inhibitors Historic Market Size by Type (2018-2023)
4.2 Global Angiotensin Converting Enzyme Inhibitors Forecasted Market Size by Type (2024-2029)
5 Angiotensin Converting Enzyme Inhibitors Breakdown Data by Application
5.1 Global Angiotensin Converting Enzyme Inhibitors Historic Market Size by Application (2018-2023)
5.2 Global Angiotensin Converting Enzyme Inhibitors Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Angiotensin Converting Enzyme Inhibitors Market Size (2018-2029)
6.2 North America Angiotensin Converting Enzyme Inhibitors Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Angiotensin Converting Enzyme Inhibitors Market Size by Country (2018-2023)
6.4 North America Angiotensin Converting Enzyme Inhibitors Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Angiotensin Converting Enzyme Inhibitors Market Size (2018-2029)
7.2 Europe Angiotensin Converting Enzyme Inhibitors Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Angiotensin Converting Enzyme Inhibitors Market Size by Country (2018-2023)
7.4 Europe Angiotensin Converting Enzyme Inhibitors Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Angiotensin Converting Enzyme Inhibitors Market Size (2018-2029)
8.2 Asia-Pacific Angiotensin Converting Enzyme Inhibitors Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Angiotensin Converting Enzyme Inhibitors Market Size by Region (2018-2023)
8.4 Asia-Pacific Angiotensin Converting Enzyme Inhibitors Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Angiotensin Converting Enzyme Inhibitors Market Size (2018-2029)
9.2 Latin America Angiotensin Converting Enzyme Inhibitors Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Angiotensin Converting Enzyme Inhibitors Market Size by Country (2018-2023)
9.4 Latin America Angiotensin Converting Enzyme Inhibitors Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Angiotensin Converting Enzyme Inhibitors Market Size (2018-2029)
10.2 Middle East & Africa Angiotensin Converting Enzyme Inhibitors Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Angiotensin Converting Enzyme Inhibitors Market Size by Country (2018-2023)
10.4 Middle East & Africa Angiotensin Converting Enzyme Inhibitors Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Angiotensin Converting Enzyme Inhibitors Introduction
11.1.4 Pfizer Revenue in Angiotensin Converting Enzyme Inhibitors Business (2018-2023)
11.1.5 Pfizer Recent Development
11.2 AstraZeneca
11.2.1 AstraZeneca Company Detail
11.2.2 AstraZeneca Business Overview
11.2.3 AstraZeneca Angiotensin Converting Enzyme Inhibitors Introduction
11.2.4 AstraZeneca Revenue in Angiotensin Converting Enzyme Inhibitors Business (2018-2023)
11.2.5 AstraZeneca Recent Development
11.3 Novartis AG
11.3.1 Novartis AG Company Detail
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Angiotensin Converting Enzyme Inhibitors Introduction
11.3.4 Novartis AG Revenue in Angiotensin Converting Enzyme Inhibitors Business (2018-2023)
11.3.5 Novartis AG Recent Development
11.4 Daiichi Sankyo, Inc
11.4.1 Daiichi Sankyo, Inc Company Detail
11.4.2 Daiichi Sankyo, Inc Business Overview
11.4.3 Daiichi Sankyo, Inc Angiotensin Converting Enzyme Inhibitors Introduction
11.4.4 Daiichi Sankyo, Inc Revenue in Angiotensin Converting Enzyme Inhibitors Business (2018-2023)
11.4.5 Daiichi Sankyo, Inc Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Detail
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Angiotensin Converting Enzyme Inhibitors Introduction
11.5.4 Sanofi Revenue in Angiotensin Converting Enzyme Inhibitors Business (2018-2023)
11.5.5 Sanofi Recent Development
11.6 Merck
11.6.1 Merck Company Detail
11.6.2 Merck Business Overview
11.6.3 Merck Angiotensin Converting Enzyme Inhibitors Introduction
11.6.4 Merck Revenue in Angiotensin Converting Enzyme Inhibitors Business (2018-2023)
11.6.5 Merck Recent Development
11.7 Abbott
11.7.1 Abbott Company Detail
11.7.2 Abbott Business Overview
11.7.3 Abbott Angiotensin Converting Enzyme Inhibitors Introduction
11.7.4 Abbott Revenue in Angiotensin Converting Enzyme Inhibitors Business (2018-2023)
11.7.5 Abbott Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Pfizer
AstraZeneca
Novartis AG
Daiichi Sankyo, Inc
Sanofi
Merck
Abbott
听
听
*If Applicable.
